EP Patent

EP2653193A1 — Method for treating macular degeneration

Assigned to Sanofi SA · Expires 2013-10-23 · 13y expired

What this patent protects

Provided herein are novel and useful methods for preventing, treating, r ameliorating a macular degeneration such as dry macular degeneration and age related macular degeneration in a patient.

USPTO Abstract

Provided herein are novel and useful methods for preventing, treating, r ameliorating a macular degeneration such as dry macular degeneration and age related macular degeneration in a patient.

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

Patent Metadata

Patent number: EP2653193A1
Jurisdiction: EP
Classification: —
Expires: 2013-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.